

# **DATA + PERSPECTIVES**

## **Clinical Investigators Explore the Current and Future Management of Triple-Negative Breast Cancer**

**Thursday, December 12, 2019**

**7:30 PM – 9:00 PM**

**San Antonio, Texas**

### **Moderator**

**Neil Love, MD**

### **Faculty**

**Erika Hamilton, MD**

**Professor Sherene Loi, MBBS, PhD**

**Mark E Robson, MD**

**Hope S Rugo, MD**

# Disclosures for Moderator Neil Love, MD

Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

# Agenda

**Module 1 – Dr Hamilton:** *Established Management Paradigms for Advanced Triple-Negative Breast Cancer (TNBC); Actionable and Other Potentially Relevant Biomarkers to Inform Decision-Making*

**Module 2 – Dr Rugo:** *Immune Checkpoint Inhibition as a Rational Therapeutic Strategy for Advanced TNBC*

**Module 3 – Dr Robson:** *Available Data with and Practical Integration of PARP Inhibition into the Care of Patients with mTNBC*

**Module 4 – Prof Loi:** *Novel Applications of Immune Checkpoint Inhibitors Alone or in Combination with Other Agents for Patients with Early and Advanced TNBC; Other Promising Agents in Late-Stage Clinical Trials*

**DATA + PERSPECTIVES**  
**Clinical Investigators Explore the Current and Future  
Management of HER2-Positive Breast Cancer**

**Friday, December 13, 2019**  
**7:30 PM – 9:00 PM**  
**San Antonio, Texas**

**Moderator**

**Neil Love, MD**

**Faculty**

**Adam M Brufsky, MD, PhD**  
**Lisa A Carey, MD**



**Sara Hurvitz, MD**  
**Martine J Piccart-Gebhart, MD, PhD**

Research  
To Practice®

# **The Second Annual Miami General Medical Oncology Symposium**

**February 21-23, 2020  
JW Marriott Miami Turnberry  
Miami, Florida**

# *Dr. Bernard Fisher, Who Revolutionized Breast Cancer Treatment, Dies at 101*



# **DATA + PERSPECTIVES**

## **Clinical Investigators Explore the Current and Future Management of Triple-Negative Breast Cancer**

**Thursday, December 12, 2019**

**7:30 PM – 9:00 PM**

**San Antonio, Texas**

### **Moderator**

**Neil Love, MD**

### **Faculty**

**Erika Hamilton, MD**

**Professor Sherene Loi, MBBS, PhD**

**Mark E Robson, MD**

**Hope S Rugo, MD**

# **Cisplatin versus Doxorubicin/Cyclophosphamide as Neoadjuvant Treatment in Germline *BRCA* Mutation Carriers (*BRCA* Carriers) with HER2-Negative Breast Cancer: Results from the INFORM Trial (TBCRC 031)**

**Tung N et al.**

**SABCS 2019;Abstract GS6-03.**

**General Session – Friday, December 13, 3:45 PM**

# **DATA + PERSPECTIVES**

## **Clinical Investigators Explore the Current and Future Management of Triple-Negative Breast Cancer**

**Thursday, December 12, 2019**

**7:30 PM – 9:00 PM**

**San Antonio, Texas**

### **Moderator**

**Neil Love, MD**

### **Faculty**

**Erika Hamilton, MD**

**Professor Sherene Loi, MBBS, PhD**

**Mark E Robson, MD**

**Hope S Rugo, MD**